Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab + Chemotherapy in HER2-Low Gastric Cancer
NCT06944496Phase 3Not yet recruiting
- Sponsor
- RemeGen
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised trial of disitamab vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by RemeGen. Primary endpoint: Progression-Free Survival at 24 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06944496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944496.